Johnson & Johnson Ovarian Cancer Victims Vow Fight to Stop J&J's Bankruptcy Scheme

 
 

Lawyers who represent more than 30,000 women who have filed lawsuits against Johnson & Johnson (NYSE:JNJ) in connection with its defective talc body powders, including the iconic Johnson's Baby Powder, say they will resist J&J's decision to use bankruptcy to avoid legal responsibility for the cancers tied to those products.

 

"It seems inconceivable that bankruptcy involving a highly profitable $500 billion company could be contemplated, let alone become reality," says   Andy Birchfield   of the   Beasley Allen   law firm, which represents thousands of women and families alleging that use of the company's Baby Powder led to ovarian cancer. "It seems hypocritical that such a company could defend a product it claims to be safe, while seeking bankruptcy protection for marketing that same product it knew to be dangerous."

 

On Thursday, J&J announced that it had created a separate subsidiary, LTL Management LLC (LTL) to "hold and manage claims in the cosmetic talc litigation." At the same time, J&J placed the subsidiary into bankruptcy, filing in the Western District of North Carolina , Charlotte Division. This venue is considered responsive to companies seeking to shield themselves from legal claims brought about by their defective products.

 

Mr. Birchfield says that recent abuses of the bankruptcy system mean that members of Congress including Sen. Elizabeth Warren (D-Mass) and Rep. Jerrold Nadler (D-NY) will join talc cancer victims in opposing J&J's bankruptcy plan. An increasing number of bankruptcy experts have voiced concerns about similar previous ploys, as corporate bankruptcies are normally reserved for struggling businesses that need relief from creditors.

 

"Right behind the Sacklers, the Boy Scouts and USA Gymnastics, here's another example of the wealthy and powerful using bankruptcy as a hiding place to protect their profits and avoid responsibility," says Birchfield.

 

According to the bankruptcy filing, Johnson & Johnson is proposing to create a $2 billion settlement fund. In the ongoing talc litigation, one single verdict for 20 women exceeded that amount, and total talc-related liabilities are estimated at more than $25 billion . Ovarian cancer is a horrific and deadly disease that exacts both an emotional and financial toll on women and their families. On average, medical expenses related to ovarian cancer caused by talc often exceed $500,000 per victim.

 

Mr. Birchfield says the filing creates an uncertain future for pending trials, including thousands of talc cases filed in multidistrict litigation in New Jersey federal court.

 

"As a firm, we are committed to challenging this petition at every level and fighting any attempt by J&J to further delay scheduled trials and prolong the suffering of thousands of ovarian cancer victims and their families," says Mr. Birchfield. "We will fight – no matter how hard and how long it takes – until these women get justice."

 

  Media Contact
  Mike Androvett  
mike@androvett.com  
800-559-4534

 

 Cision View original content: https://www.prnewswire.com/news-releases/johnson--johnson-ovarian-cancer-victims-vow-fight-to-stop-jjs-bankruptcy-scheme-301400995.html  

 

SOURCE Beasley Allen Law Firm

 
 

News Provided by Canada Newswire via QuoteMedia

The Conversation (0)
illustration of brain and cell phone.

BlinkLab Completes First Patient Test for US Autism Diagnostic Study

Digital healthcare company BlinkLab (ASX:BB1) has tested the first patient in its US autism diagnostic study, which is geared at validating the company's Dx1 test as a diagnostic aid for clinicians.

BlinkLab states in its Wednesday (March 12) release that the study is the largest digital diagnostic trial for autism in the US, with its aim being to support the early detection of developmental conditions like autism.

The first patient test took place at PriMED Clinical Research in Dayton, Ohio. PriMED, a division of PriMED Physicians, is one of two clinical sites selected for the study’s initial phase, which is targeting 100 patients.

Keep reading...Show less
HeraMED Signs Strategic Collaboration Agreement with Garmin Health

HeraMED Signs Strategic Collaboration Agreement with Garmin Health

HeraMED Limited (ASX: HMD), a medical data and technology company leading the digital transformation of maternity care, is delighted to announce it has entered into a collaboration agreement with Garmin (NYSE: GRMN), a leading global provider of smartwatches and GPS-enabled products, aimed at enhancing remote pregnancy monitoring and expanding the range of health data available to expectant mothers and their healthcare providers.

Keep reading...Show less
Cardiologist wearing virtual reality glasses.

2 Biggest Medical Device ETFs in 2025

Exchange-traded funds (ETFs) are a popular investment strategy, and generally contain a variety of publicly traded companies under one stock symbol, often with a focus on a specific sector.

Depending on the ETF, investors may be able to track up-and-coming companies, get exposure to top firms or a mix of both. Aside from stocks, some ETFs also track commodities or bonds.

In the healthcare industry, medical device ETFs bring together companies that go to great lengths to develop pharmaceutical-based technology that can improve the lives of patients.

Keep reading...Show less
Cyclomedica

Cyclopharm Signs US Agreement with HCA Healthcare for Technegas®

Cyclopharm Limited (ASX: CYC) is pleased to announce the signing of a major contract with Hospital Corporation of America Healthcare (HCA), one of the largest single healthcare providers in the United States. This agreement marks a significant milestone for the company which will allow the deployment of Technegas® in up to 169 nuclear medicine departments across HCA’s extensive network.1

Keep reading...Show less
CONNEQT App Launches in USA as Pulse Deliveries Commence

CONNEQT App Launches in USA as Pulse Deliveries Commence

Cardiex Limited (CDX:AU) has announced CONNEQT App Launches in USA as Pulse Deliveries Commence

Download the PDF here.

Female doctor with clipboard talking to smiling female patient at hospital.

Revolutionizing Women's Health: Antifungal Innovation Brings New Investment Opportunities

The intersection of women's health and antifungal innovation represents a pivotal moment in healthcare, offering both transformative medical advancements and compelling investment opportunities.

The groundbreaking developments in antifungal treatments specifically targeting women's health issues present a substantial market potential, resulting in rising investor interest in this rapidly evolving sector.

Despite comprising half the global population, women face unique health challenges that have historically received insufficient attention and investment. Among these health challenges, vaginal candidiasis stands out as a persistent and widespread issue affecting millions of women worldwide.

Keep reading...Show less

Latest Press Releases

Related News

×